Keyphrases
Neurofibromatosis
100%
Inhibitory Effect
100%
Glioblastoma Cell Lines
100%
Implications for Treatment
100%
Pirfenidone
100%
Dose Effect
42%
Epidermal Growth Factor Receptor
42%
Neurofibromatosis Type 1 (NF-1)
42%
Neurofibromatosis Type I
42%
Receptor Phosphorylation
28%
Flow Cytometry
14%
Clinical Investigation
14%
Apoptosis
14%
Antifibrotic
14%
Tumor
14%
Malignant Glioma
14%
Oral Agents
14%
Biological Properties
14%
Treatment Options
14%
Proliferation Inhibition
14%
Autosomal Dominant Disorder
14%
Western Blotting
14%
Drug Treatment
14%
Antitumor Effect
14%
Glioma Cell Lines
14%
Propidium Iodide
14%
Complex Tumor
14%
Growing Cells
14%
Cell Proliferation Inhibition
14%
Phosphotyrosine
14%
Tritiated Thymidine
14%
Gelatin Zymography
14%
MiRNA Inhibitors
14%
Similar Biologics
14%
Matrix Metallopeptidase 2
14%
MTS Assay
14%
Plexiform Neurofibroma
14%
Malignant Glioma Cells
14%
Thymidine Assay
14%
Casein Zymography
14%
Medicine and Dentistry
Glioblastoma Cell Line
100%
Neurofibromatosis
100%
Pirfenidone
100%
Epidermal Growth Factor Receptor
42%
Neurofibromatosis Type I
42%
Neoplasm
28%
Biological Product
14%
Drug Therapy
14%
Glioblastoma
14%
Programmed Cell Death
14%
Cell Proliferation
14%
Flow Cytometry
14%
Gelatin
14%
Zymography
14%
Matrix Metalloproteinase
14%
Casein
14%
Phosphotyrosine
14%
MTS Assay
14%
Plexiform Neurofibroma
14%
Malignant Glioma Cell Line
14%
DNA Synthesis Inhibition
14%
Propidium Iodide
14%
Thymidine
14%
Autosomal Dominant Disorder
14%
Western Blotting
14%
Neuroscience
Cell Line
100%
Pirfenidone
100%
Neurofibromatosis
100%
Epidermal Growth Factor Receptor
42%
Neurofibromatosis Type 1
42%
Receptor Phosphorylation
28%
Propidium Iodide
14%
Thymidine
14%
Autosomal Dominant Disorder
14%
Neurofibroma
14%
Cell Proliferation
14%
Matrix Metalloproteinase
14%
Casein
14%
Phosphotyrosine
14%
Gelatin
14%
DNA Synthesis Inhibition
14%
Zymography
14%
Flow Cytometry
14%
Western Blotting
14%
Pharmacology, Toxicology and Pharmaceutical Science
Glioblastoma
100%
Neurofibromatosis
100%
Pirfenidone
100%
Neurofibromatosis Type 1
42%
Epidermal Growth Factor Receptor
42%
Neoplasm
28%
Western Blot
14%
Propidium Iodide
14%
Flow Cytometry
14%
Pharmacotherapy
14%
Biological Product
14%
Gelatin
14%
Phosphotyrosine
14%
Casein
14%
Neurofibroma
14%
Matrix Metalloproteinase
14%
Thymidine
14%
Autosomal Dominant Disorder
14%